Literature DB >> 4604936

Preparation of test cells for the antiglobulin test.

F Stratton, V I Rawlinson.   

Abstract

Erythrocytes may be coated with blood group antibodies with or without reacting complement or sometimes apparently with complement alone. This may occur in vivo in such conditions as autoimmune acquired haemolytic anaemia, haemolytic disease of the newborn, or after transfusions of incompatible blood. It may occur in vitro also by the deliberate sensitization of erythrocytes during laboratory serological investigations. Blood group antibodies may be of immunoglobulin types gammaM, gammaA, or gammaG; we have never seen gammaD antibodies. The presence of these antibodies on the erythrocyte surface, together with complement components or the presence of complement components alone, may be detected by the direct antiglobulin test where sensitization occurs in vivo or by the indirect antiglobulin test where there is sensitization in vitro.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4604936      PMCID: PMC478127          DOI: 10.1136/jcp.27.5.359

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  27 in total

1.  Zymosan coated particles used to prepare anti-beta-1C.

Authors:  F Stratton
Journal:  Vox Sang       Date:  1966 Mar-Apr       Impact factor: 2.144

2.  Antigenic determinants of human beta-1c and beta-1g-globulins.

Authors:  C West; N C Davis; J Forristal; J Herbst; R Spitzer
Journal:  J Immunol       Date:  1966-04       Impact factor: 5.422

3.  Autoimmune haemolytic anaemias. I. Serological studies with pure anti-immunoglobulin reagents.

Authors:  C P Engelfriet; D Beckers; J J van Loghem
Journal:  Clin Exp Immunol       Date:  1968-09       Impact factor: 4.330

4.  19S gamma M, followed by 7S gamma G anti-Jk antibodies associated with pregnancy.

Authors:  F Stratton; D S Smith; V I Rawlinson
Journal:  Clin Exp Immunol       Date:  1968-01       Impact factor: 4.330

5.  The demonstration in human serum of "conglutinogen-activating factor" and its effect on the third component of complement.

Authors:  P J Lachmann; H J Müller-Eberhard
Journal:  J Immunol       Date:  1968-04       Impact factor: 5.422

6.  The action of the first component of complement on cells sensitized with blood group antibody.

Authors:  F Stratton; V I Rawlinson
Journal:  Br J Haematol       Date:  1965-09       Impact factor: 6.998

7.  Detection of complement components on unlysed erythrocytes from acid hemolysis and thrombin test reactions in paroxysmal nocturnal hemoglobinuria.

Authors:  D E Jenkins; W N Christenson; R L Engle
Journal:  J Clin Invest       Date:  1966-05       Impact factor: 14.808

8.  Interaction between human serum complement and normal human red cells at low ionic strength.

Authors:  F Stratton; V I Rawlinson
Journal:  Nature       Date:  1965-07-17       Impact factor: 49.962

9.  Three naturally-occurring inhibitors of components of complement in guinea pig and rabbit serum.

Authors:  N Tamura; R A Nelson
Journal:  J Immunol       Date:  1967-09       Impact factor: 5.422

10.  The reaction mechanism of beta-1C-globulin (C'3) in immune hemolysis.

Authors:  H J Müllerèberhard; A P Dalmasso; M A Calcott
Journal:  J Exp Med       Date:  1966-01-01       Impact factor: 14.307

View more
  4 in total

1.  Serological blind spots for variants of human IgG3 and IgG4 by a commonly used anti-immunoglobulin reagent.

Authors:  Heather L Howie; Meghan Delaney; Xiaohong Wang; Lay See Er; Gestur Vidarsson; Tamara C Stegmann; Linda Kapp; Jenna N Lebedev; Yanyun Wu; James P AuBuchon; James C Zimring
Journal:  Transfusion       Date:  2016-09-16       Impact factor: 3.157

2.  Lymphocytes bearing Fc gamma receptors in rheumatoid arthritis. II. Phenotypic characterisation of mononuclear cells forming Facb rosettes in RA.

Authors:  V R Winrow; L J Eales; N D Hall; N J Goulding; I M Hunneyball
Journal:  Ann Rheum Dis       Date:  1985-01       Impact factor: 19.103

3.  False-positive antiglobulin tests in healthy subjects and in hospital patients.

Authors:  J Freedman
Journal:  J Clin Pathol       Date:  1979-10       Impact factor: 3.411

4.  Complement-activating rheumatoid-factor-containing complexes in patients with rheumatoid vasculitis.

Authors:  C J Elson; D G Scott; D R Blake; P A Bacon; P D Holt
Journal:  Ann Rheum Dis       Date:  1983-04       Impact factor: 19.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.